Millions of people fall ill with the flu every year, and adults age 65 and older are at higher risk of developing serious ...

CSL Seqirus revenue is projected to benefit from the supply of H5 avian flu vaccines in the second half, with FLUAD launch preparations underway in Germany. CSL Vifor is set to maintain its ...

Sales of CSL's flu vaccines were down by double digits in the first half amid a fall in immunisation rates since the COVID-19 pandemic.

Revenue from CSL's flu vaccine-making business dropped sharply in the first half of the financial year amid a significant fall in immunisation rates, particularly in the US. CSL Seqirus brought in ...

It also launched in Switzerland and listed on Australia's National Immunization Program. FLUAD. STIKO, Germany's highly influential technical advisory group, has given FLUAD a preferential ...

While still robust, CSL half-year results last Weds revealed impact of an “alarming” fall off in 'flu vax rates, especially ...

Vaccine aversion in the US has put a hole in CSL revenues in the first half, with the company saying the flu season is shaping up to be the worst in 15 to 20 years. But ironically, the company has ...

证券之星消息，丽珠集团(000513)02月14日在投资者关系平台上答复投资者关心的问题。投资者：购买广东华南疫苗流感疫苗，RSV疫苗比流感疫苗更有价值为什么没有收购？丽珠集团董秘：尊敬的投资者，您好！华南疫苗研发的四价流感重组蛋白疫苗为全球首创的流 ...

A weak vaccine result dragged on CSL's H1 result but analysts focus on an improving plasma product margin and solid growth ...

Objectives To compare the efficacy of influenza vaccines of any valency for adults 60 years and older. Design and setting Systematic review with network meta-analysis (NMA) of randomised controlled ...

But ironically, the company has benefited from winning tenders to counter the impact of the avian flu pandemic which has swept the globe, with most of that revenue to be recognised in the second half.